International audienceObjectives - Soluble suppression of tumorigenecity 2 (sST2) is prognostic in acute and chronic heart failure with reduced ejection fraction (HFrEF) but less studied in HF with preserved EF (HFpEF). We evaluated sST2 concentrations, correlations with biomarkers and echocardiographic measures of diastolic and systolic function, and associations with outcomes in HFpEF and HFrEF. Design and results - A total of 193 subjects from three different cohorts were included. Eighty-six HFpEF patients were obtained from the Karolinska Rennes (KaRen) study, 86 patients with HFrEF were recruited from referrals to Karolinska University Hospital for advanced assessment of HF, and 21 controls were included (ClinicalTrials.gov Identifie...
Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and...
BackgroundHeart failure (HF) with preserved ejection fraction (HFpEF) is a growing public health bur...
OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regardin...
International audienceObjectives - Soluble suppression of tumorigenecity 2 (sST2) is prognostic in a...
Objective: To study the prognostic value of soluble Suppression of Tumorigenicity-2 (sST2) in heart ...
Heart failure (HF), with steadily increasing incidence rates and mortality in an ageing population, ...
Chronic heart failure with preserved ejection fraction (HFpEF), with a left ventricular ejection fra...
International audienceSoluble suppression of tumorigenicity-2 (sST2) is a biomarker widely investiga...
BACKGROUND Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and ...
Soluble suppression of tumorigenesis-2 (sST2) is released in response to vascular congestion and inf...
: In recent years, there has been growing interest in the risk stratification for heart failure, and...
Abstract Aims Biomarkers are not recommended until now to guide the management of patients with hear...
Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and...
BackgroundHeart failure (HF) with preserved ejection fraction (HFpEF) is a growing public health bur...
OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regardin...
International audienceObjectives - Soluble suppression of tumorigenecity 2 (sST2) is prognostic in a...
Objective: To study the prognostic value of soluble Suppression of Tumorigenicity-2 (sST2) in heart ...
Heart failure (HF), with steadily increasing incidence rates and mortality in an ageing population, ...
Chronic heart failure with preserved ejection fraction (HFpEF), with a left ventricular ejection fra...
International audienceSoluble suppression of tumorigenicity-2 (sST2) is a biomarker widely investiga...
BACKGROUND Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and ...
Soluble suppression of tumorigenesis-2 (sST2) is released in response to vascular congestion and inf...
: In recent years, there has been growing interest in the risk stratification for heart failure, and...
Abstract Aims Biomarkers are not recommended until now to guide the management of patients with hear...
Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and...
BackgroundHeart failure (HF) with preserved ejection fraction (HFpEF) is a growing public health bur...
OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regardin...